Sen. Bernie Sanders (I-Vt.), chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee, on Wednesday launched an investigation into the “outrageously high prices” of Novo Nordisk’s respective diabetes and weight loss drugs, Ozempic and Wegovy. On Wednesday, Sanders penned a letter to Novo Nordisk’s chief executive officer, Lars Fruergaard Jørgensen, notifying him of Read this story
